Gilead Sciences is making strides in HIV prevention with a fresh approach aimed at engaging the Black community. Following the FDA’s approval of Yeztugo for pre-exposure prophylaxis (PrEP), the company is seizing the moment to address specific demographic challenges. The drug’s phase 3 trials demonstrated an impressive efficacy rate, with over 99.9% of participants remaining HIV negative, prompting optimism about its potential impact on ending the HIV epidemic.
In the second quarter of 2026, Gilead’s PrEP sales surpassed the $1 billion mark, with Yeztugo contributing a significant $232 million. However, analysts have raised concerns about the drug’s long-term success, particularly regarding its acceptance within populations with historically low PrEP usage, such as the Black community.
A New Campaign: “Up to Date”
To bridge this gap, Gilead has launched the “Up to Date” campaign, leveraging humor to normalize discussions about HIV prevention. Comedians Nicole Byer and Devon Walker are featured in the campaign, which focuses on real-life dating scenarios to engage the audience. This approach stands in stark contrast to conventional pharmaceutical marketing, which often relies heavily on statistics and clinical data.
Ashley Gildea, Gilead’s U.S. business unit head, highlighted the campaign’s departure from traditional marketing, emphasizing the need for authentic storytelling to foster dialogue. By creating relatable narratives, the campaign seeks to change perceptions and encourage proactive health discussions among Black individuals.
Addressing Historical Disparities
The campaign aims to resonate with an audience that faces significant barriers to healthcare. Despite comprising only 13.5% of the U.S. population, Black Americans represented 39% of those living with HIV and 38% of new diagnoses in 2023. Furthermore, only 15% of PrEP users were Black individuals in 2024. These statistics underscore the urgent need for targeted outreach to a community that has been disproportionately affected by systemic inequities.
Gildea noted that the high rates of HIV diagnoses among Black individuals are not merely a result of personal choices, but rather a reflection of broader societal challenges. Mistrust in healthcare systems, stemming from a history of discrimination and inadequate care, complicates efforts to improve health outcomes.
A Commitment to Health Equity
Gilead’s mission extends beyond just providing medications. The company is dedicated to dismantling the societal barriers that hinder access to care. Gildea emphasized their commitment to advancing health equity, which includes educational initiatives and community investments designed to engage Black communities meaningfully.
The campaign “Up to Date” is an evolution of Gilead’s previous efforts, specifically the “Care for the Culture” initiative, which also targeted Black communities. By collaborating with Black creatives, Gilead has ensured that the campaign authentically reflects the lived experiences of its audience.
Humor as a Tool for Engagement
Utilizing humor in health communication can make difficult subjects more approachable. By embedding HIV messaging within relatable everyday experiences, Gilead aims to lower the barriers that often accompany discussions about sexual health. Gildea believes that using community voices to frame these conversations creates a more engaging and effective way to communicate vital health information.
The Path Forward for PrEP
Since the approval of Truvada as the first FDA-approved PrEP medication in 2012, there has been a clear correlation between increased PrEP coverage and reduced HIV diagnosis rates. However, Gilead acknowledges that there is still much work to be done. Although the CDC estimates that 2.2 million people in the U.S. could benefit from PrEP, only about 600,000 were using it in 2024.
To enhance accessibility, Gilead is also pursuing a weekly oral formulation of Yeztugo, in addition to its injectable version. This move aims to cater to a broader audience, as daily oral medications currently dominate the PrEP market.
Conclusion: A Pivotal Moment for HIV Prevention
Gilead’s innovative approach to engaging the Black community represents a significant shift in the conversation around HIV prevention. By addressing cultural barriers and utilizing humor, the company is working to normalize discussions that have long been stigmatized. As Gilead continues to push for increased access to PrEP and health equity, the potential to make a lasting impact on the HIV epidemic remains within reach.
- Gilead has launched the “Up to Date” campaign to engage the Black community in HIV prevention discussions.
- The campaign features humor and relatable scenarios to normalize conversations about sexual health.
- Black Americans are disproportionately affected by HIV, representing a significant portion of new diagnoses.
- Gilead is committed to dismantling societal barriers to healthcare and advancing health equity.
- The company is pursuing a weekly oral formulation of Yeztugo to enhance accessibility for potential users.
Read more → www.yahoo.com
